Free tool
FAERS Monitor: Lorbrena
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210868 or its brand name (Lorbrena, Lorlatinib). Reports on generic versions are filed under their own applications.
Reports
7,455
Serious
6,225
84% of reports
Hospitalization
1,619
Death reported
2,070
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,486
- neoplasm progression620
- off label use457
- hallucination447
- weight increased433
- blood cholesterol increased381
- dyspnoea293
- malignant neoplasm progression285
- oedema280
- fatigue273
- oedema peripheral270
- peripheral swelling229
- neuropathy peripheral212
- cognitive disorder206
- memory impairment204
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 56 |
| 2019 | 552 |
| 2020 | 508 |
| 2021 | 595 |
| 2022 | 692 |
| 2023 | 918 |
| 2024 | 1,225 |
| 2025 | 1,565 |
| 2026 | 1,336 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,704 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 620 | 51.2 | 47.5 | 29,981 |
| blood cholesterol increasedSignal | 381 | 23.2 | 21.1 | 8,039 |
| hallucinationSignal | 447 | 16.8 | 15.4 | 6,623 |
| oedemaSignal | 280 | 14.6 | 13.0 | 3,535 |
| cognitive disorderSignal | 206 | 12.5 | 10.9 | 2,163 |
| malignant neoplasm progressionSignal | 285 | 7.9 | 7.0 | 1,706 |
| neuropathy peripheralSignal | 212 | 6.3 | 5.5 | 942 |
| oedema peripheralSignal | 270 | 6.3 | 5.6 | 1,193 |
| weight increasedSignal | 433 | 5.5 | 5.0 | 1,588 |
| deathSignal | 1,486 | 4.9 | 4.7 | 4,757 |
| peripheral swellingSignal | 229 | 4.2 | 3.7 | 558 |
| memory impairmentSignal | 204 | 4.2 | 3.7 | 496 |
| off label use | 457 | 1.5 | 1.3 | 72 |
| dyspnoea | 293 | 1.5 | 1.3 | 43 |
| fatigue | 273 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.